WO2004077048A1 - グリコシド結合含有化合物中の糖の分離方法、糖分離システム、糖分離用試薬キット、糖分離用標準化試料、および、評価システム - Google Patents
グリコシド結合含有化合物中の糖の分離方法、糖分離システム、糖分離用試薬キット、糖分離用標準化試料、および、評価システム Download PDFInfo
- Publication number
- WO2004077048A1 WO2004077048A1 PCT/JP2004/000508 JP2004000508W WO2004077048A1 WO 2004077048 A1 WO2004077048 A1 WO 2004077048A1 JP 2004000508 W JP2004000508 W JP 2004000508W WO 2004077048 A1 WO2004077048 A1 WO 2004077048A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sugar
- solution
- separation
- sample
- sample solution
- Prior art date
Links
- 235000000346 sugar Nutrition 0.000 title claims abstract description 372
- 238000000926 separation method Methods 0.000 title claims abstract description 109
- 150000001875 compounds Chemical class 0.000 title claims abstract description 43
- 229930182470 glycoside Natural products 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title claims description 77
- 239000012488 sample solution Substances 0.000 claims abstract description 90
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 87
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 87
- 239000000243 solution Substances 0.000 claims abstract description 60
- 239000000523 sample Substances 0.000 claims abstract description 49
- 239000003513 alkali Substances 0.000 claims abstract description 26
- 239000012670 alkaline solution Substances 0.000 claims description 42
- 150000001720 carbohydrates Chemical class 0.000 claims description 41
- 239000003153 chemical reaction reagent Substances 0.000 claims description 35
- 238000011156 evaluation Methods 0.000 claims description 17
- 239000011259 mixed solution Substances 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 abstract description 124
- 230000035484 reaction time Effects 0.000 abstract description 13
- 238000005342 ion exchange Methods 0.000 abstract description 12
- 238000002347 injection Methods 0.000 abstract description 5
- 239000007924 injection Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 2
- 238000000354 decomposition reaction Methods 0.000 description 36
- 238000004458 analytical method Methods 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 23
- 102000015728 Mucins Human genes 0.000 description 17
- 108010063954 Mucins Proteins 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 210000001913 submandibular gland Anatomy 0.000 description 15
- 239000000126 substance Substances 0.000 description 13
- 238000004401 flow injection analysis Methods 0.000 description 11
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 238000012916 structural analysis Methods 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 238000006911 enzymatic reaction Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 239000003638 chemical reducing agent Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 150000005846 sugar alcohols Chemical class 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 238000003379 elimination reaction Methods 0.000 description 6
- 150000008163 sugars Chemical class 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 229930186217 Glycolipid Natural products 0.000 description 5
- 208000007976 Ketosis Diseases 0.000 description 5
- 150000001323 aldoses Chemical class 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 238000005520 cutting process Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 125000001976 hemiacetal group Chemical group 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 150000002584 ketoses Chemical class 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 239000002547 new drug Substances 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- XFDUHJPVQKIXHO-UHFFFAOYSA-N 3-aminobenzoic acid Chemical class NC1=CC=CC(C(O)=O)=C1 XFDUHJPVQKIXHO-UHFFFAOYSA-N 0.000 description 3
- 108700023372 Glycosyltransferases Proteins 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108010026552 Proteome Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 3
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 3
- 238000006698 hydrazinolysis reaction Methods 0.000 description 3
- -1 ion ion Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 235000011118 potassium hydroxide Nutrition 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 238000010504 bond cleavage reaction Methods 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 150000001719 carbohydrate derivatives Chemical class 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 150000001793 charged compounds Chemical class 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000002360 explosive Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 239000003014 ion exchange membrane Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 229940051875 mucins Drugs 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000005375 photometry Methods 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000575 proteomic method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000036632 reaction speed Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical class NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000589565 Flavobacterium Species 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 102000028180 Glycophorins Human genes 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241000220304 Prunus dulcis Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 239000012805 animal sample Substances 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000012668 chain scission Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 102000013361 fetuin Human genes 0.000 description 1
- 108060002885 fetuin Proteins 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 239000010842 industrial wastewater Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010666 regulation of catalytic activity Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical group C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8836—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving saccharides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
Definitions
- the present invention has, for example, an extremely diverse and important role in physiological activities.
- the present invention relates to a method for separating saccharides in a dalicoside bond-containing compound such as a glycoprotein and a saccharide separation system used therefor, a saccharide separation reagent kit, a standardized sample for saccharide separation, and an evaluation system.
- a dalicoside bond-containing compound such as a glycoprotein and a saccharide separation system used therefor, a saccharide separation reagent kit, a standardized sample for saccharide separation, and an evaluation system.
- Glycoconjugates such as glycoproteins, proteoglycans, and glycolipids are an important group of biological substances that are formed when various sugar chains bind to proteins and lipids.
- Glycoproteins which are a group of these glycoconjugates, are broadly classified into serotype glycoproteins and mucin-type glycoproteins. Most proteins in serum except for albumin have carbohydrates linked to Asn of Asn-X-Ser / Thr residues in the protein via N-linkage. For this reason, glycoproteins having this type of binding mode are called serotype glycoproteins or N-linked glycoproteins.
- the sugar chains that bind to the N-linked glycoprotein are called N-linked sugar chains.
- mucus secreted from glandular tissues such as salivary glands and submandibular glands
- proteins that are the main components of mucosal tissues on the inner surface of the digestive tract, such as the stomach and small intestine are linked to carbohydrates via Ser / Thr through 0-bond are doing.
- this type of connection Glycoproteins are called mucin-type glycoproteins and O-linked glycoproteins.
- a sugar chain that binds to an o-linked glycoprotein is called an o-linked sugar chain.
- N-linked sugar chains such as IgG and IgE
- those containing only 0-linked sugar chains such as submandibular gland mucin
- those containing N-linked sugar chains such as erythropoietin
- glycoproteins in vivo include, for example, the preservation of the conformation of the protein in IgG, the protection of mucins from xenobiotics, the regulation of the rate of elimination of blood in the porphyrin mouth, the liver of the ash mouth glycoprotein. It plays an extremely versatile and important role in physiological activities. In addition, these sugar chains are widely distributed on the cell membrane surface and intercellular matrix, and are thought to play a central role in biological information networks. There are many points.
- sugar chains of glycoproteins perform various functions.To elucidate the functions, the sugar chains bound to the glycoproteins are separated from the protein, and the separated sugar chains are separated. After separation, the structure must be analyzed. As for the separation and structural analysis of sugar chains, recent developments in analytical instruments and structural analysis have been remarkable, and high-performance liquid separation methods such as high-speed liquid chromatography and capillary electrophoresis have been used. Sugar chains derived from glycoproteins can be separated. The separated glycans can be analyzed by matrix-assisted laser desorption time-of-flight mass spectrometry, electrospray mass spectrometry, and molecular weight measurement. It has become relatively easy to perform structural analysis by sequencing using ion ion analysis and high-field nuclear magnetic resonance.
- sugar chains separated from glycoproteins have some problems, such as the difficulty in obtaining the amount required for analysis, but use the latest analytical equipment. As a result, many methods have been provided for the structural analysis.
- a chemical method and an enzymatic method are mainly used as a method for separating an N-linked sugar chain from an N-linked glycoprotein bound to asparagine.
- the hydrazinolysis method is a method in which a target glycoprotein is dissolved in anhydrous hydrazine and heated at a high temperature (100 ° C or higher) for a long time to separate sugar chains.
- a high temperature 100 ° C or higher
- anhydrous hydrazine is very toxic and explosive and requires extremely careful handling.
- Several methods are known for separating sugar chains from glycoproteins using hydrazine, but in all cases, after a high-temperature reaction for 3 to 24 hours, hydrazine is distilled off and sugar chains are removed.
- Another enzymatic method for separating N-linked sugar chains from N-linked glycoproteins is to use a glycopeptide obtained by previously digesting a glycoprotein with a protease such as trypsin as a substrate.
- a sugar chain is cleaved using N-daricanase F found in a microorganism of the genus Flavobacterium or N-glycamidase A found in almond seeds.
- the enzymatic method is safe, unlike the hydrazinolysis method.
- O-linked glycoprotein is dissolved in a high-concentration aqueous solution of alkali and incubated for a long time (usually 48 hours or more) to cut the sugar chain. is there.
- a 0.1 M to 0.5 M sodium hydroxide aqueous solution is usually used as the aqueous solution, but due to the high concentration, the sugar chains separated from the glycoprotein are converted to the hemiacetal group at position 1. Based on-Has a fatal problem of undergoing elimination and decomposing.
- a reducing agent for example, NaBH4
- the alkali solution to carry out a sugar chain scission reaction.
- the reducing end of the generated sugar chain is not a hemiacetal structure but a sugar alcohol, so that the post-treatment is extremely complicated.
- sugar alcohols have the disadvantage that they cannot be labeled with fluorescent substances or reagents that absorb ultraviolet light, which are required for high-sensitivity analysis.
- the hydrazinolysis method is often used recently as a modification of the alkaline decomposition method, but it still requires a long time for the reaction and subsequent treatment, and requires the use of easily explosive reagents. Versatility.
- the separated 0-linked sugar chain causes a] -elimination reaction, so that mild conditions must be used to prevent the sugar chain from being further decomposed.
- the reaction must be performed for a long time under the following conditions. This is a major obstacle to the application to proteome or proteomics analysis, which requires clinical analysis or high-throughput analysis that requires handling a large number of samples.
- sugar chains have not been elucidated in this way.
- the monosaccharides constituting the sugar chains each have 4 to 5 hydroxyl groups, and their structures may be extremely diverse.
- the biggest reason is that no simple and quick method for separating sugar chains from protein has been found.
- glycoproteins are complexes of proteins and sugar chains with molecular weights ranging from tens of thousands to hundreds of thousands, and over the past 30 years, excellent methods for separating sugar chains have been sought.
- no excellent general-purpose method has been found.
- the present invention has been made in view of the above problems, and an object of the present invention is to provide a method for separating a saccharide which can easily and efficiently separate a saccharide by cleaving a daricoside bond in a short time.
- a sugar separation reagent kit a sugar separation reagent kit, a standardized sample for bran separation, and a sugar evaluation method and system for performing proteome or proteomic analysis requiring clinical analysis and high-throughput analysis. is there. Disclosure of the invention
- the present inventor applied the flow-indication analysis method to allow the alkali solution to come into contact with a sample solution containing a sugar-containing compound such as a glycoprotein while flowing in the flow channel.
- a sample solution containing a sugar-containing compound such as a glycoprotein
- the present inventors have found that the reaction time can be drastically shortened, the amount of reagents used in the reaction can be minimized, and the environmentally friendly glycosidic bond in the molecule can be cleaved. was completed.
- the sugar separation method of the present invention is a sugar separation method for cleaving glycosidic bonds of a sample solution containing a glycosidic bond-containing compound and separating sugar from the sample solution, wherein the sugar is separated from the sample solution.
- the method is characterized in that the sample solution is introduced into the fluid solution that flows by flowing, and the alkali solution and the sample solution are mixed while flowing in the flow path.
- the method for separating saccharides of the present invention utilizes a flow injection analysis (Flow Injection Analysis: hereinafter abbreviated as FIA method) to combine an alcohol solution and a sample solution containing a compound having a glycosidic bond. The reaction is performed while flowing in the flow channel.
- FIA method Flow Injection Analysis: hereinafter abbreviated as FIA method
- the FIA method means that an analysis sample solution is injected into a tube with an inner diameter of about 0.5 to 1.0 mm, and a reaction reagent is mixed and reacted with the sample solution flow, followed by absorption photometry, fluorescence photometry, etc. This is a method of detecting an analysis target by the method.
- the FIA method is also specified in ISO and JISK0126. At present, the FIA method is mainly used as a method for analyzing inorganic harmful substances in soil, water and sewage, and industrial wastewater.
- the sample solution containing the dalicoside bond-containing compound comes into contact with the solution while flowing in the channel. That is, the reaction of cleaving the glycosidic bond of the glycosidic bond-containing compound contained in the sample solution proceeds while flowing in the flow channel.
- the reaction time for separating the saccharide from the sample solution can be reduced to the order of minutes.
- the time required for the conventionally used reaction for separating sugar chains from glycoproteins was on a daily basis (more than one day and night). The time can be dramatically reduced.
- the separated sugar is a sugar alcohol.
- the sugar in the glycosidic bond-containing compound can be separated as ketose or aldose. Therefore, the sugar can be easily isolated.
- the method for separating a saccharide according to the present invention is particularly suitable for separating a saccharide and a glycoside bond other than the saccharide in a glycosidic bond-containing compound molecule efficiently in a short time.
- the glycoside bond-containing compound is a glycoconjugate, especially a glycoprotein. It is preferable that Glycoproteins are classified as N-linked or ⁇ -linked glycoproteins, and the present invention is applicable to any glycoprotein.
- Glycoconjugates such as glycoproteins and glycolipids are biological macromolecules (biopolymers), and have various functions such as recognition between cells, regulation of enzyme activity, and expression of hormone-like activity. These functions are thought to play an important role in sugar chains in glycoconjugates.
- the sugar chain present on the cell surface changes its structure along with canceration, and thus is an important marker for distinguishing normal cells from cancer cells. Since the functions of sugar chains are often unknown, studies on the separation of sugar chains from glycoconjugates and the elucidation of their functions are being vigorously conducted. However, the enzymatic method and the alkaline decomposition method conventionally used to separate sugar chains from glycoconjugates have extremely long reaction times (daily units), so many samples can be analyzed in a short time. Can not do it.
- the reaction time of the sugar separation method of the present invention is extremely short (minutes), it can be easily applied to a large number of samples. Therefore, the speed of separating sugar chains in glycoconjugates using the sugar separation method of the present invention and analyzing the structure and function thereof is dramatically improved. As a result, it can be expected to be applied to the development of new drugs, the discovery of various diseases, and the application to clinical analysis and proteome analysis that requires high-throughput analysis.
- the decomposition reaction of the separated saccharide proceeds, and if the temperature is too low, the glycosidic bond is cleaved. The time gets longer.
- Decomposition reaction can be prevented.
- glycoside bonds in the sample solution can be cleaved in a shorter time and more efficiently, and saccharides can be isolated.
- a glycoside bond is cleaved and a sugar is separated from the sample solution while flowing the sample solution and the aqueous solution into the channel. That is, the separated sugar solution includes an alkaline solution.
- the sugar separated from the sample solution it is preferable to label the sugar separated from the sample solution. That is, it is preferable to lead the separated sugar to a labeled derivative.
- the separated sugar solution usually contains one or more sugars. Therefore, for example, in order to determine the structure of a sugar whose structure is unknown, it is preferable to separate each sugar from a solution of separated sugars containing a plurality of sugars (including sugar chains).
- the saccharide separated by the saccharide separation method of the present invention is ketose or aldose which can form a hemiacetal structure. For this reason, the separated saccharide can easily react with, for example, a compound containing an amino group, and can be easily led to a labeled saccharide derivative. Since the sugar derivative labeled in this manner can be easily detected, highly sensitive analysis becomes possible.
- the “preparation of sugar chains” means, for example, that a large amount of a sample solution is used and that the sugar chains contained in the sample solution are isolated.
- the decomposition reaction of the separated sugar can be prevented, so that the sugar chain can be efficiently prepared regardless of the amount of the sample solution. That is, sugar chains can be efficiently extracted from the sample solution. This makes it possible, for example, to prepare sugar chains involved in the disease and to analyze the structure of the sugar chains, thereby elucidating the mechanism of the disease and contributing to the development of new drugs.
- the sugar separation system of the present invention comprises: a capillary for flowing a sample solution containing a glycosidic bond-containing compound and an alkaline solution; an alkaline solution supply means for continuously supplying the alkaline solution to the capillary; It is characterized by comprising an introduction means for introducing a sample solution, a temperature control means for controlling the temperature of the solution flowing through the capillary, and a removal means for removing the residual force contained in the solution flowing out of the capillary.
- the sugar separation system of the present invention is an application of the FIA method. That is, the alkaline solution is continuously supplied into the capillary by the alkaline solution supply means, and a certain amount of the sample solution is supplied from the sample solution introduction means provided in the middle of the capillary to flow the alkaline solution. Introduce inside.
- the sample solution diffuses while flowing through the capillary by the flow of the alkaline solution, and is mixed with the alkaline solution, and the glycosidic bond cleavage reaction proceeds.
- the temperature control means heats the mixed solution of the sample solution and the alkaline solution flowing through the capillary. As a result, the glycosidic bond is cleaved in a short time.
- the thin tube that has passed through the temperature control means is released from the heating state by the temperature control means and is immediately cooled. This can prevent the decomposition reaction of the cut sugar by alkali. Further, the alkaline solution contained in the solution containing the cut sugar is removed by the removing means. As a result, the decomposition reaction of the sugar due to the alkali can be reliably prevented, and the solution can be isolated as a solution containing only the cleaved sugar.
- the sugar separation system of the present invention is capable of supplying a sample solution or an alkali solution to a thin tube (liquid sending), introducing the sample solution into the thin tube, mixing the sample solution with the alkaline solution, The reaction is performed in-line.
- the sugar separation system of the present invention further includes detection means for detecting sugar in the solution flowing out of the capillary.
- the detecting means provided upstream of the removing means detects the sugar in the solution flowing out of the capillary.
- the inside diameter of the thin tube is 0.1 to 2 mm, and the length of the thin tube heated by the temperature control means is 1 to 2 Om.
- the reaction can be carried out in a short time, and the decomposition reaction of the sugar due to the alkali can be prevented, so that the sugar can be more efficiently separated from the sample solution.
- the sugar separation reagent kit (sugar separation reagent set) of the present invention
- a sugar separation reagent kit for use in such a sugar separation method or sugar separation system comprising: a preparation reagent for preparing a sample solution; and an alkali solution having a predetermined concentration. I have.
- a sample solution can be prepared only by adding a glycosidic bond-containing compound to this reagent kit. Therefore, the sugar can be separated from the sample solution in a shorter time by using the sugar separation method and the sugar separation system according to the present invention. Further, since the sugar separation reagent kit also contains an aqueous solution of a predetermined concentration, the sugar separation method and the sugar separation system can be performed under the same conditions.
- preparation reagent is a reagent used for preparing a sample solution, which includes solid and liquid reagents such as a solution for preparing a sample solution, as well as a sample solution. It also includes devices such as a gas introduced into the device, and a force ram used for preparing a sample solution from a biological sample such as blood or urine.
- the standardized sample for sugar separation according to the present invention is a standardized sample for bran separation for use in the method for separating sugar according to the present invention or the sugar separation system, wherein the standardized sample comprises a compound having a known saccharide structure. It is.
- the standardized sample for sugar separation is composed of a compound containing a glycoside bond having a known bran structure.
- complex carbohydrates with known sugar chains such as glycoproteins such as pest submucosal mucin, fetuin, swallow's nest, erythrocyte glycophorin, and glycolipids such as glycemic glycolipid and glycosphingolipid, chemicals Sugar-containing compounds or derivatives thereof that have been synthetically synthesized.
- the result of separating sugar from a sample solution with an unknown bran structure and the sugar content can be estimated by comparing the result of separation of the sugar from the standardized sample for release.
- the standardized sample for sugar separation is included in the sugar separation reagent kit. This makes it possible to compare the separation results of a sample solution with an unknown sugar structure and the separation results of a standardized sample for sugar separation under the same conditions, so that the sugar structure contained in the sample solution is more reliable. Can be estimated.
- a sugar structural analysis can be performed in a short time.
- the steps from separation of the sugar in the sample solution to structural analysis of the sugar can be performed continuously.
- FIG. 1 is a configuration diagram showing a schematic configuration of an inflow chemical reaction system according to the present invention.
- FIG. 10 is a view showing a result obtained by cutting off the reaction tube and a result when the length of the reaction tube is 1.5 m.
- FIG. 3 (a) Fig. 3 (b) shows the use of the in-flow chemical reaction system shown in Fig. 1 to change the temperature and the length of the reaction tube in the thermostat to change the sugar chain from the mucous membrane of the submandibular gland.
- FIG. 9 is a view showing a result of disconnecting the reaction tube, and the length of the reaction tube. Is a diagram showing the result of 3 m.
- FIG. 4 is a view showing a result obtained by cutting off, and a result showing a case where the length of a reaction tube is 5 m.
- FIG. 5 (a) Fig. 5 (b) shows the use of the in-flow chemical reaction system shown in Fig. 1 to change the temperature and the length of the reaction tube in the thermostat to change the sugar chain from mucin of the submandibular gland.
- FIG. 9 is a view showing a result obtained by cutting off, and showing a result when the length of the reaction tube is 10 m.
- FIG. 6 is a MALD I-TOF MS spectrum of a sugar chain cleaved from a mouse submandibular gland mucin using the in-flow chemical reaction system of FIG.
- FIG. 7 is a view showing main sugar chains contained in the submandibular gland mucin and the results of MALDI-TOF MS in FIG.
- FIG. 8 is a diagram showing a result of analyzing a sugar chain cleaved from mucous membrane of the submandibular gland by HPLC using the inflow chemical reaction system of FIG. 1 by HPLC.
- Fig. 9 shows the results of analysis of O-linked sugar chains separated from He1a cells and U933 cells using the in-flow chemical reaction system of Fig. 1 in Example 2. It is a graph shown.
- A: in-flow chemical reaction system (sugar separation system), 1: alkaline solution, 2: inert gas cylinder, 3: pump (alkaline solution supply means), 4: sample injection Equipment (sample introduction means), 5: mixing equipment, 6: constant temperature bath (temperature control means), 7: reaction tube (capillary tube / flow path), 8: detector (detection means), 9: recording unit, 10 a1 0 b: Switching valve, 11 a 'lib: Waste section, 12: Ion exchange column (removal means), 13: Sample tube, 14: Sugar chain (sugar).
- the method for separating a sugar chain from a glycoprotein of the present invention comprises contacting a sample solution containing a glycosidic bond-containing compound with an aqueous solution while flowing in a flow channel to obtain a glycoside in the glycosidic bond-containing compound. This method breaks down cosidic bonds and efficiently separates sugar from the sample solution.
- glycoside bond-containing compound refers to a compound having a partial structure in which the molecule is glycosidically bonded to sugar.
- examples of the dalicoside bond-containing compound include glycoconjugates in which a sugar is combined with a peptide, protein, or lipid, or a base, that is, glycoproteins, glycolipids, nucleic acids, and the like.
- the sugar in the glycosidic bond-containing compound may be a monosaccharide or a sugar that forms a sugar chain such as an oligosaccharide or a polysaccharide.
- Glycosidic bonds can be formed, for example, by reducing the sugar at the reducing end (ie, the anomeric hydroxyl group) and at the functional group of the sugar or other compound (hydroxyl (—OH), amino (_NH 2 ), thiol (1-SH) )) And formed by dehydration condensation.
- the hydroxyl group, amino group, and thiol group can also be referred to as functional groups capable of forming an acetal with aldose or ketose. Therefore, the glycoside bond-containing compound is a compound containing one or more O-glycosidic bonds, N-glycosidic bonds, or S-glycosidic bonds. 7
- the glycoside bond-containing compound is a glycoprotein
- a method for separating a sugar chain contained in the glycoprotein will be described as an example.
- alkali decomposition has been mainly used as a method for separating sugar chains from glycoproteins.
- the separated sugar chains are further decomposed by the alkali, so that the reaction had to be performed under mild conditions in order to prevent the decomposition reaction as much as possible.
- a two-stage reaction proceeds as shown in the following formulas (1) and (2).
- a decomposition reaction is performed in the presence of a reducing agent in order to suppress a decomposition reaction (for example, an elimination reaction) of a sugar chain as shown in the formula (2).
- a decomposition reaction for example, an elimination reaction
- the reducing end of the sugar chain is also reduced by the reducing agent, and the finally obtained sugar chain is obtained as a sugar alcohol. That is, the sugar chain finally obtained is obtained as a sugar alcohol in which the carbonyl group of aldose or ketose has been reduced.
- the final sugar chain is a linear sugar alcohol that cannot form a hemiacetal structure, so that the post-treatment is very complicated in the alkaline decomposition method.
- the inventor of the present application performs only the cleavage reaction of the glycosidic bond of the formula (1), and separates the sugar chain separated in the formula (1) from the reaction system before the decomposition reaction of the formula (2) proceeds. It was thought that the sugar chain could be efficiently obtained if it could be obtained, and thus came to invent such an in-flow chemical reaction system.
- This in-flow chemical reaction system performs the reaction of the formula (1) at a stretch at a high temperature, and separates the sugar chain from the reaction system before the reaction of the formula (2) ′ proceeds. This greatly reduces the reaction time.
- FIG. 1 is a diagram showing a schematic configuration of an in-flow chemical reaction system (sugar chain separation device. Sugar separation system) A.
- the basic configuration of this system is as follows: a pump for continuously feeding the alkaline solution 1 to the reaction tube 7 (solution supplying means) 3, a sample injection section (sample solution introducing means) 4, a thermostat ( Temperature control means) 6, Reaction tube (capillary tube / flow path) 7, Detector 8, Switching valve 10a / 10b, and Al-rich solution 1, which is an ion exchange column (removal means), are inactive
- the gas cylinder 2 is filled with an inert gas such as nitrogen and argon, and the pump 3 flows through the system at a constant flow rate.
- a sample injecting section 4 is arranged downstream of the pump 3, and the sample solution containing the glycoprotein is introduced into the reaction solution flowing continuously through the reaction tube 7 at a constant flow rate.
- the mixing device 5 mixes the sample solution and the alkaline solution for a predetermined time. Then, the mixed solution is supplied to the thermostat 6. Then, the mixed solution is kept at a constant temperature by the thermostat 6. Cut sugar chains from glycoproteins The detachment reaction occurs in the thermostat 6. In other words, the mixed solution proceeds through the reaction tube 7 in the thermostat 6 at a certain temperature while cutting the glycoside bonds of the glycoprotein to separate the sugar chains.
- the reaction tube 7 After passing through the constant temperature bath 6, the reaction tube 7 is released from the heating of the constant temperature bath 6, returns to room temperature, and the mixed solution in the reaction tube 7 is rapidly cooled. For this reason, in the reaction tube 7 after passing through the thermostat 6, the reaction rate at which the glycosidic bond is cleaved is reduced to a negligible level. Furthermore, since the reaction time in the thermostatic oven 6 is very short, the 8 elimination reaction of the separated sugar chains is almost negligible.
- the in-flow chemical reaction system A since the alkaline solution flows at a constant flow rate by the pump 3, the time required for the sample solution introduced from the sample injection unit 4 to elute from the thermostatic bath 6 can be easily calculated. Further, the mixed solution eluted from the reaction tube 7 that has passed through the thermostatic bath 6 is monitored by the detector 8, and at the time when the separated sugar chains are eluted, the valve 10a is connected to the waste (disposing part) 11 Switch from a side to ion exchange column 12 side. Thus, only the mixed solution containing the sugar chain is passed through the ion exchange column 12 filled with the cation exchange resin. As a result, the Al force in the mixed solution containing sugar chains The sugar chain 14 can be collected in the sample tube 13. If another detector 8 is provided between the ion-exchange force ram 12 and the pulp 10b, the pulp 10b is switched while monitoring with the detector 8, so that the sugar chain 1 is surely removed. Only the solution containing 4 can be collected in the sample tube 13.
- the separation reaction of sugar which takes 48 hours at 30 ° C and doubles the reaction rate at 10 ° C, was performed at 90 ° C using in-flow chemical reaction system A, Since the reaction rate is considered to increase as a power of temperature, the reaction rate at 90 ° C is 64 times the reaction rate at 30 ° C.
- the O-linked sugar can be extremely efficiently.
- the chains can be broken.
- the separation of the sugar chain is completed by passing through the thermostat 6 in 3 minutes (180 seconds). Therefore, compared with the reaction time of 48 hours required in the conventional alkali decomposition reaction, the present invention made it possible to shorten the reaction time to actually reach 1/1000.
- the reaction temperature immediately returns to room temperature because the reaction tube 7 is an extremely thin tube (0.3 mm in inner diameter). Further, since the solution is passed through an ion-exchange column 12 (volume: 1 mL) to remove (desalinate) the alkaline solution, O-linked sugar chains 14 can be efficiently collected in the sample tube 13.
- reaction rate at which the glycosidic bond between the sugar and the sugar in the glycoprotein is cleaved is much lower than the reaction rate at which the dalicoside bond between the protein and the sugar is cleaved.
- the sugar is not cleaved. That is, the structure of the sugar chain contained in the sample solution is maintained. In this way, sugar chains can be separated efficiently from the sample solution containing the glycoprotein in a very short time, and the separated sugar chains can be efficiently collected.
- the sample solution containing the glycoprotein is added to the reaction tube 7 in which the alkaline solution 1 flows continuously at a constant speed.
- the sugar chains in the glycoprotein are cut off in the reaction tube 7 in the constant temperature bath 6 maintained at a constant temperature. Since the time required for the mixed solution of the sample solution and the alkaline solution 1 to flow out of the thermostat 6 is extremely short (usually within 3 minutes), the eluate eluted out of the thermostat 6 is transferred to an ion exchange column. By passing through eluate, alkali can be removed from the eluate.
- the ion exchange ram 12 can be said to be a post-treatment device after separating the sugar chains from the sample solution.
- the in-flow chemical reaction system A is a very useful system that can easily, quickly, and efficiently separate a saccharide from a sample solution. Therefore, it can also be used as an automatic sugar chain sequencer for determining the primary sequence of an unknown or known sugar chain.
- the in-flow chemical reaction system A all operations are performed in the in-line reaction system, so that post-treatments such as neutralization and desalting required by conventional methods are not required.
- the in-flow chemical reaction system A can easily achieve high throughput by using an autosampler and a fraction collector.
- the sugar chains 14 collected in the sample tube 13 are aldose or ketose, A cetal structure can be formed. Therefore, the separated sugar chain 14 can be easily labeled and led to a sugar derivative, so that it can be used for highly sensitive detection. Therefore, even if a plurality of types of sugar chain derivatives are contained in the sample tube 13, the sugar chain derivatives can be separated by, for example, HPLC. Then, analysis of each separated sugar chain derivative can be easily performed. Analysis techniques are so advanced that sugar chains can be analyzed by, for example, mass spectrometry, NMR, HPLC, etc. This enables the analysis of the sugar chain structure, such as the determination of the primary sequence of the sugar chain.
- the method of labeling is not particularly limited.For example, if a fluorescent substance, an enzyme, a radioisotope, a luminescent substance, an ultraviolet absorbing substance, a spin labeling agent, etc. are bound to a sugar, Good. Thereby, even when impurities are present in the separated saccharide solution or when a plurality of saccharides are contained, the labeled saccharide can be separated from the solution.
- a compound containing an amino group for example, an aminobenzene derivative such as 3-aminobenzoic acid, a 2-aminobenzene derivative, an aminononaphthalene derivative, an APTS (9 —Amino virene 1,4,6 trisulfonate) can be used.
- an aminobenzene derivative such as 3-aminobenzoic acid, a 2-aminobenzene derivative, an aminononaphthalene derivative, an APTS (9 —Amino virene 1,4,6 trisulfonate)
- the sugar derivative can be detected with high sensitivity, so that the labeled sugar derivative can be separated from the separated sugar solution.
- the separation data between the standard data and the sample solution can be obtained.
- the structure of the sugar contained in the sample solution can be estimated. For example, if standard data is prepared by separating labeled sugar derivatives by HPLC, The sugar structure can be estimated by the retention time of the sample solution separated under the same conditions.
- saccharide structural analysis can be performed.
- Alkaline solutions include, for example, inorganic alkalis such as hydroxides of alkaline metals such as sodium hydroxide, potassium hydroxide, lithium hydroxide, and potassium hydroxide, and hydroxides of alkaline earth metals. And organic alcohols such as nitrogen-containing compounds such as ammonia and triethylamine.
- inorganic alkalis such as hydroxides of alkaline metals such as sodium hydroxide, potassium hydroxide, lithium hydroxide, and potassium hydroxide
- hydroxides of alkaline earth metals such as sodium hydroxide, potassium hydroxide, lithium hydroxide, and potassium hydroxide
- organic alcohols such as nitrogen-containing compounds such as ammonia and triethylamine.
- the concentration of the alkaline solution is preferably from 0.05 to 2.0 M, and more preferably from 0.1 to 0.5 M.
- the reaction tube 7 has a spiral shape in order to make effective use of the space in the thermostat 6, but the shape of the reaction tube 7 is not particularly limited.
- the flow rate of the pump 3 is not particularly limited as long as it is appropriately set according to the length and diameter of the reaction tube 7. Usually, the flow rate is preferably from 0.05 to 5 mL, more preferably from 0.1 to 1.0 mL. As a result, a sugar protein and an alkali solution serving as a sample are introduced into the reaction tube 7 at a constant speed, and the sugar chains can be separated.
- W 200
- the temperature of the thermostat 6 should be kept in the range of room temperature to 150 ° C. Of these, the temperature is preferably maintained at 30 to 100 ° C, more preferably 70 to 90 ° C. As a result, the sugar chain can be separated from the glycoprotein in a short time, and the decomposition of the separated sugar chain can be prevented.
- the inner diameter of the reaction tube 7 is preferably small. Specifically, the inner diameter is preferably set to 0.05 mm to 2 mm, and more preferably 0.1 mm to 0.5 mm. Accordingly, since the heating and cooling of the mixed solution does not cause a mud, the separation reaction of the sugar chain efficiently proceeds, and the decomposition of the separated sugar chain can be prevented.
- the length of the reaction tube 7 inside the constant temperature bath 6 is preferably from lm to 20 m, more preferably from 3 m to 10 m. This Thus, the separation reaction of the bran chains proceeds efficiently, and the decomposition of the separated sugar chains can be prevented.
- the material of the reaction tube 7 is not particularly limited as long as the material is stable to the alkaline solution, such as Teflon (registered trademark).
- the mixing device 5 mixes the sample glycoprotein solution and the Arikari solution for a predetermined time, and then introduces the mixed solution into the reaction tube 7 of the thermostat 6.
- a configuration in which a mixed solution obtained by mixing a sample solution and an alkaline solution in advance is introduced from the sample injector 4 may be adopted. In this case, the mixing device 5 becomes unnecessary.
- the scale can be easily scaled up, and the sugar chain can be recovered in a shorter time. it can. Further, by installing a fraction collector after the ion exchange ram 12, a fully automatic sugar separation system can be configured.
- an antibody ram Downstream or upstream of the ion exchange ram 12, an antibody ram is provided in which an antibody having a certain sugar chain as the antigen is immobilized, and the effluent from the capillary is passed through the antibody column. It can be determined whether or not a sugar chain serving as an antigen is contained. That is, the sugar chain antigen present in the sample solution can be detected. Further, by washing the antibody column and breaking the antigen-antibody bond, the antigen bound to the antibody can be isolated.
- any sugar-containing compound having a glycosidic bond in the molecule can be used to separate a sugar (bran chain) from any compound. be able to.
- the separation speed of sugar chains can be dramatically increased, and the reaction efficiency can be significantly improved.
- the use of the in-flow chemical reaction device A can reduce the reaction time, which was conventionally required for the separation of sugar chains over a day or night, to within 3 minutes. That is, the operation involved in the reaction can be simplified by a factor of 500 or more.
- the reducing end can be easily labeled to lead to a saccharide derivative, and can be applied to highly sensitive analysis. In addition, this derivative could be used in pharmaceutical ingredients.
- At least a preparation reagent for preparing a sample solution and an alkaline solution having a predetermined concentration are kitted to form a kit for sugar separation.
- the sugar separation reagent kit may further contain detection reagents and various reagents for easily separating sugar.
- glycoside bond-containing compound having a known sugar structure for example, a mucosin underlined mucin in Examples described later as a standardized sample for sugar separation.
- This sugar separation standardized sample is often not included in the sugar separation reagent kit. More preferred. This makes it possible to compare the separation results of a sample solution with an unknown sugar structure with the separation results of a standardized sample for sugar separation under the same conditions, so that the sugar structure contained in the sample solution can be more reliably determined. Can be estimated. As described above, by using the sugar separation reagent kit and the sugar separation standardized sample according to the present invention in a sugar separation method and a sugar separation system, the structural analysis of bran can be performed in a short time. In addition, the steps from separation of the sugar in the sample solution to structural analysis of the sugar can be performed continuously.
- the sugar separation system (the present system) and the sugar separation method of the present invention have the following advantages, and are extremely useful.
- This system greatly shortens the time required to separate sugar chains from glycoproteins, which previously required a long time (daily unit). That is, the separation of sugar chains from glycoproteins, which has conventionally taken at least one day or more, can be performed in minutes.
- glycoconjugates mainly requires purification (isolation) of glycoconjugates; separation of sugar chains from glycoconjugates; analysis of sugar chains.
- purification isolation
- separation of sugar chains from glycoconjugates separation of sugar chains from glycoconjugates
- analysis of sugar chains e.g., sugar chains from glycoconjugates.
- the development of technology relating to the separation of sugar chains has been delayed, and has become the rate-limiting step in glycoconjugate analysis. This system is extremely useful because sugar chains can be separated in a much shorter time (500 times or more) than before.
- This system uses an inline reactor to inject a sample solution containing complex carbohydrates while pumping an alkaline solution (reaction reagent) with a pump, and to separate sugar chains from the sample solution. Therefore, after the sample containing complex carbohydrates is adsorbed on the column, an alkaline solution is allowed to flow through the column to react. It is different from the conventional method.
- glycoprotein compounds eg, glycoprotein drugs
- the quality of glycoprotein compounds can be easily evaluated. It will also contribute to the development of glycoprotein biopharmaceuticals, the evaluation of sugar chain-related compounds and their application to clinical testing methods, and the development of new sugar chain-related drugs. That is, the present system or the method for separating saccharides can also be described as an evaluation system or an evaluation method for evaluating a sample.
- “evaluate the sample” means, for example, identification (estimation) of the type and content of the saccharide contained in the sample based on the separation results of the sugar chains in the sample; identification (estimation) of the cell derived from the sample Estimation of the involvement of sugar chains in disease based on comparison of sugar chains between normal cells and diseased cells; clinical tests; That is, according to the above-described evaluation system or evaluation method, for example, it is possible to evaluate the quality of sugars and samples, to evaluate the difference in the sugar chain abundance ratio between normal cells and diseased cells, and to determine whether or not a disease has been developed. .
- the above-described evaluation system or evaluation method can be applied to a clinical analysis or the like that tracks changes in sugar chains of glycoconjugates present in a biological sample such as serum or tissue extract.
- the sample it is preferable to evaluate the sample based on the abundance ratio of the sugar contained in the sample.
- the types of sugar chains contained in the sample are substantially the same as in the examples described later. For this reason, it may be difficult to evaluate the sample (identify the sample) using only the type of sugar. Therefore, a highly reliable evaluation can be performed by evaluating the ratio of the sugar content in the sample (existence ratio of multiple sugars). It becomes possible.
- this system when this system is used as an evaluation system for bran, evaluation can be performed in a short time by using the above-described reagent kit and standardized sample.
- this system can quickly prepare sugar chains that are difficult to synthesize from animal samples, and can be applied to the production of raw materials for new sugar chain-containing drugs.
- the present system can separate sugar chains from N-linked glycoproteins as well as O-linked glycoproteins. For this reason, any type of sugar chain can be analyzed with a single device, and this is a useful system that can replace conventional devices.
- this system separates sugar chains in a flow injection system and has a short reaction time, so that the amount of reagents used can be significantly reduced.
- the present system can be said to be an extremely useful invention in which the cost of the reagent used is reduced and the environment is taken into consideration.
- this system may open up a whole new field in the pathological testing and clinical testing industries based on glycan abnormalities.
- this system makes it extremely easy to perform sugar chain analysis, which was previously difficult to apply to daily analysis.For example, qualitative or quantitative changes in glycosyltransferases such as cancer and inflammation As a result, the analysis of blood and urine sugar chains and the tracking of sugar chain changes in cancer cells and inflammatory tissues are expected to expand into a completely new field of clinical chemistry.
- the present system tracks the changes in sugar chains and recognizes the fate of glycosyltransferases and sugar hydrolases involved in sugar chain synthesis and recognizes sugar chains. It can be expected to be applied to the development of new drugs based on the control of proteins (receptors). In addition, if the structure of a sugar chain having a new function is clarified by this system, there is a very high possibility that an antibody against the sugar chain can be used for an antibody drug or detection and screening of the sugar chain.
- this system uses an in-flow chemical reaction device, it can be easily scaled up by placing an appropriate permeation membrane / ion exchange membrane or an electro-desalination device behind the reaction thermostat. It is.
- This makes it possible to continuously carry out the glycan detachment reaction using in-flow chemical reactor A, using readily available proteins (eg, ovalbumin, egg yolk IgY, submandibular mucin, porcine gastric mucosa mucin, etc.) as raw materials. By doing so, it becomes possible to prepare a large amount of sugar chains derived from glycoproteins, which were conventionally difficult to obtain. The obtained sugar chain can be expected as a material for enhancing the function of proteinaceous drugs.
- proteins eg, ovalbumin, egg yolk IgY, submandibular mucin, porcine gastric mucosa mucin, etc.
- Submandibular gland mucin is a typical mucin-type protein that is commercially available as a biochemical reagent and contains various sugar chains as shown in FIG.
- a solution (10 ⁇ L) of mucin (0.1 mg) in the submandibular gland was converted to the inflow solution shown in Fig. 1.
- Alkali decomposition was performed using a chemical reaction system. In this system, a 0.5 M aqueous solution of lithium hydroxide was used as an alkaline solution at a flow rate of 5 ml / min.
- the reaction solution collected by the low-strength ram of the ion-exchange resin is filtered using a sialic acid present in a filtration solution (low molecular weight, containing oligosaccharides) obtained through an ultrafiltration membrane with a molecular weight of 10,000 cutoff.
- Figures 2 (a) to 5 (b) show the results of an investigation of the efficiency (reaction tube length, reaction temperature) of the in-flow chemical reactor in alkaline decomposition.
- the filtration solution obtained through the ultrafiltration membrane was the lower layer, and the cleaning solution for the ultrafiltration membrane (the reaction solution which did not pass through the ultrafiltration membrane) was the upper layer. Then, the content of sugar chains contained in each layer was calculated from the measurement results of the fluorescence of each layer.
- the efficiency of the submandibular gland mucin is highest when the reaction tube length is 5 m and the reaction temperature is 90 ° C or the reaction tube length is 10 m and the reaction temperature is 80 ° C. Sugar chains were successfully separated from mucin.
- Figure 7 shows the theoretical molecular weight (the molecular weight below the structural formula) and the predicted molecular ion of the 3-oligobenzoic acid derivative (3-AB in Figure 7) of the major oligosaccharide found in the submandibular gland ([M + H] +) and although sodium showed list of additional molecular ions ([M + N a] +), the sugar chain mixture obtained by using the inflow chemical reaction system MALDI- In TOF MS (Flow system A column), these predicted ions were clearly observed.
- the "standard” column shows the molecular weight of the sugar chains separated by the conventional method.
- Fig. 8 shows the results of HPLC analysis of the sugar chain of 3-aminobenzoic acid derivative.
- the HPLC analysis conditions were as follows: a column (0DS (4.6 x 150 mm)) eluent (0.1 M ammonium acetate buffer (pH 6.0); linear concentration gradient elution with acetonitrile (2%-1 8%)), flow rate (1 ml / min), and detection (fluorescence detection (excitation wavelength: 305 nm, fluorescence wavelength: 405 nm)).
- the supernatant (50 ⁇ L) after centrifugation was subjected to alkaline digestion of the glycoprotein bran chains using the in-flow chemical reaction system shown in Fig. 1 in substantially the same manner as in Example 1. .
- the flow rate was 0.5 ml / min
- the aqueous solution of 0.5 M lithium hydroxide was 2.5 m
- the reaction temperature was 70 ° C.
- the HPLC analysis conditions were a polymer type amino column (manufactured by Showa Denko; 4.0 x 250 mm), an eluent (5% acetic acid-12% triethylamine-10% acetonitrile mixed solvent), and flow rate. (1.0 ml / min) and detection (fluorescence detection (excitation wavelength: 350 nm, emission wavelength: 425 nm)) were analyzed by the gradient method.
- the membrane fraction of both cells was subjected to in-line glycolysis of glycoproteins by the in-line method, and the sugar chains obtained were fluorescently labeled and analyzed for O-linked sugar chains using an amino column. It is a graph of the result of having performed. As shown in the figure, the major sugar chains are relatively consistent between the two cells, but the sugar chain ratios are different. Therefore, even if the sugar chains and types contained in the cells are the same, the cells can be evaluated based on the abundance ratio of the sugar chains.
- the separation of sugar chains from glycoproteins which has conventionally required more than one day or more, can be reduced to minutes. Therefore, it has many advantages as described above, and it is essential for proteomic analysis of post-genomes or glycosylation that is essential for proteomics. In addition to greatly streamlining analysis and saving labor, high-precision analysis is also possible.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Sustainable Development (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005502815A JP4283272B2 (ja) | 2003-02-28 | 2004-01-21 | グリコシド結合含有化合物中の糖の分離方法、糖分離システム、および、評価システム |
CA002517162A CA2517162A1 (en) | 2003-02-28 | 2004-01-21 | Method of separating sugar from compound having glycoside bond, sugar separation system, sugar separation agent kit, standardized sample for sugar separation and assessment system |
EP04703941A EP1635174A1 (en) | 2003-02-28 | 2004-01-21 | Method of separating sugar from compound having glycoside bond, sugar separation system, sugar separation agent kit, standardized sample for sugar separation and assessment system |
US10/546,961 US7700745B2 (en) | 2003-02-28 | 2004-01-21 | Method for separating carbohydrate in glycoside-linkage-having compound, carbohydrate separating system, carbohydrate separating reagent kit, standard sample for carbohydrate separation, and evaluation system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-54752 | 2003-02-28 | ||
JP2003054752 | 2003-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004077048A1 true WO2004077048A1 (ja) | 2004-09-10 |
Family
ID=32923473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/000508 WO2004077048A1 (ja) | 2003-02-28 | 2004-01-21 | グリコシド結合含有化合物中の糖の分離方法、糖分離システム、糖分離用試薬キット、糖分離用標準化試料、および、評価システム |
Country Status (5)
Country | Link |
---|---|
US (1) | US7700745B2 (ja) |
EP (1) | EP1635174A1 (ja) |
JP (1) | JP4283272B2 (ja) |
CA (1) | CA2517162A1 (ja) |
WO (1) | WO2004077048A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006329938A (ja) * | 2005-05-30 | 2006-12-07 | Shimadzu Corp | 糖鎖切り出し装置 |
JP2008539413A (ja) * | 2005-04-26 | 2008-11-13 | レイモンド, エー. ドウェック, | 自動化糖鎖フィンガープリント戦略 |
JP2009216609A (ja) * | 2008-03-12 | 2009-09-24 | Sumitomo Bakelite Co Ltd | 糖鎖試料調製方法 |
JP2009236600A (ja) * | 2008-03-26 | 2009-10-15 | National Institute Of Advanced Industrial & Technology | 糖化合物の質量分析法 |
US8039208B2 (en) | 2005-04-26 | 2011-10-18 | National Institute For Bioprocessing Research And Training Limited (Nibrt) | Automated strategy for identifying physiological glycosylation markers(s) |
JP2013529780A (ja) * | 2010-06-25 | 2013-07-22 | インペリアル イノベイションズ リミテッド | 小型hplc装置 |
WO2018062167A1 (ja) * | 2016-09-27 | 2018-04-05 | 国立研究開発法人産業技術総合研究所 | 糖タンパク質の糖鎖遊離法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060269979A1 (en) * | 2005-04-26 | 2006-11-30 | Dwek Raymond A | High throughput glycan analysis for diagnosing and monitoring rheumatoid arthritis and other autoimmune diseases |
US20140061133A1 (en) * | 2012-08-31 | 2014-03-06 | Joseph Lewis HERMAN | Method and Apparatus for Split-Flow-Mixing Liquid Chromatography |
TW202111322A (zh) * | 2019-05-31 | 2021-03-16 | 美商建新公司 | 新穎二維lc—ms/ms系統 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0687904A (ja) * | 1990-06-21 | 1994-03-29 | Oxford Grycosyst Ltd | N‐グリカン及びo‐グリカンの放出及び単離 |
JP2003339393A (ja) * | 2002-05-27 | 2003-12-02 | Japan Science & Technology Corp | オリゴ糖(塩)の製造方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56128569A (en) | 1980-03-12 | 1981-10-08 | Toshiba Battery Co Ltd | Fabrication of battery |
JP2948069B2 (ja) * | 1993-09-20 | 1999-09-13 | 株式会社日立製作所 | 化学分析装置 |
JP3505906B2 (ja) | 1996-04-04 | 2004-03-15 | 東ソー株式会社 | 糖化ヘモグロビン分析装置 |
US6444233B1 (en) * | 1998-05-19 | 2002-09-03 | Research Development Foundation | Triterpene compositions and methods for use thereof |
JP3735666B2 (ja) * | 2001-12-27 | 2006-01-18 | 独立行政法人産業技術総合研究所 | 糖類混合物の同時分析方法及びそれに用いる分析装置 |
JP4012800B2 (ja) | 2002-10-23 | 2007-11-21 | 財団法人川村理化学研究所 | 液体クロマトグラフィーデバイス、及び試料導入方法 |
-
2004
- 2004-01-21 EP EP04703941A patent/EP1635174A1/en not_active Withdrawn
- 2004-01-21 US US10/546,961 patent/US7700745B2/en not_active Expired - Fee Related
- 2004-01-21 JP JP2005502815A patent/JP4283272B2/ja not_active Expired - Fee Related
- 2004-01-21 CA CA002517162A patent/CA2517162A1/en not_active Abandoned
- 2004-01-21 WO PCT/JP2004/000508 patent/WO2004077048A1/ja active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0687904A (ja) * | 1990-06-21 | 1994-03-29 | Oxford Grycosyst Ltd | N‐グリカン及びo‐グリカンの放出及び単離 |
JP2003339393A (ja) * | 2002-05-27 | 2003-12-02 | Japan Science & Technology Corp | オリゴ糖(塩)の製造方法 |
Non-Patent Citations (1)
Title |
---|
KARLSSON N.G. & PACKER N.H.: "Analysis of O-Linked Reducing Oligosaccharides Released by an In-line Flow System", ANALYTICAL BIOCHEMISTRY, vol. 305, 2002, pages 173 - 185, XP002258674 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008539413A (ja) * | 2005-04-26 | 2008-11-13 | レイモンド, エー. ドウェック, | 自動化糖鎖フィンガープリント戦略 |
US8039208B2 (en) | 2005-04-26 | 2011-10-18 | National Institute For Bioprocessing Research And Training Limited (Nibrt) | Automated strategy for identifying physiological glycosylation markers(s) |
JP2006329938A (ja) * | 2005-05-30 | 2006-12-07 | Shimadzu Corp | 糖鎖切り出し装置 |
JP2009216609A (ja) * | 2008-03-12 | 2009-09-24 | Sumitomo Bakelite Co Ltd | 糖鎖試料調製方法 |
JP2009236600A (ja) * | 2008-03-26 | 2009-10-15 | National Institute Of Advanced Industrial & Technology | 糖化合物の質量分析法 |
JP2013529780A (ja) * | 2010-06-25 | 2013-07-22 | インペリアル イノベイションズ リミテッド | 小型hplc装置 |
WO2018062167A1 (ja) * | 2016-09-27 | 2018-04-05 | 国立研究開発法人産業技術総合研究所 | 糖タンパク質の糖鎖遊離法 |
JPWO2018062167A1 (ja) * | 2016-09-27 | 2019-06-24 | 国立研究開発法人産業技術総合研究所 | 糖タンパク質の糖鎖遊離法 |
CN109983034A (zh) * | 2016-09-27 | 2019-07-05 | 国立研究开发法人产业技术综合研究所 | 糖蛋白的糖链游离法 |
US11325935B2 (en) | 2016-09-27 | 2022-05-10 | National Institute Of Advanced Industrial Science And Technology | Method for liberating sugar chain from glycoprotein |
Also Published As
Publication number | Publication date |
---|---|
JP4283272B2 (ja) | 2009-06-24 |
JPWO2004077048A1 (ja) | 2006-06-08 |
US20060211849A1 (en) | 2006-09-21 |
EP1635174A1 (en) | 2006-03-15 |
CA2517162A1 (en) | 2004-09-10 |
US7700745B2 (en) | 2010-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gaunitz et al. | Recent advances in the analysis of complex glycoproteins | |
JP5552421B2 (ja) | エキソグリコシダーゼを用いるn−グリカンの特性決定法 | |
Pabst et al. | Comparison of fluorescent labels for oligosaccharides and introduction of a new postlabeling purification method | |
An et al. | Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer | |
EP1514107B1 (en) | Methods for quantitative proteome analysis of glycoproteins | |
JP5116837B2 (ja) | グリカンを評価するためのms法 | |
Brooks | Strategies for analysis of the glycosylation of proteins: current status and future perspectives | |
JP5500067B2 (ja) | 糖鎖標識方法 | |
US8927263B2 (en) | Derivatization of PNGase F released glycans on an HPLC chip | |
EP2135090A1 (en) | Proteolytic release of glycans | |
US20150233903A1 (en) | Solid phase glycan and glycopeptide analysis and microfluidic chip for glycomic extraction, analysis and methods for using same | |
KR20100098500A (ko) | 당쇄 자동 전처리 장치 | |
EP3519832B1 (en) | Labeled glycan amino acid complexes useful in lc-ms analysis and methods of making the same | |
Yang et al. | Solid‐phase glycan isolation for glycomics analysis | |
WO2013192530A2 (en) | Methods and reagents for glycoproteomics | |
JP4283272B2 (ja) | グリコシド結合含有化合物中の糖の分離方法、糖分離システム、および、評価システム | |
KR101672717B1 (ko) | 인간 타액 특이적 당사슬을 이용한 인간 타액 검증방법 | |
Kattla et al. | 3.41 Protein Glycosylation | |
KR101544591B1 (ko) | 질량분석기 및 크로마토그래피 시스템을 이용한 초고속 당 정성 및 정량 분석 방법 | |
KR101923662B1 (ko) | 비인간형 당사슬 NeuGc를 포함하는 시알산 고감도 분석방법 및 이를 이용한 분석용 킷트 | |
Cho et al. | Determination of Isomeric Glycan Structures by Permethylation and Liquid Chromatography–Mass Spectrometry (LC-MS) | |
Bank et al. | Liquid chromatography–mass spectrometry of carbohydrates derivatized with biotinamidocaproyl hydrazide | |
Song | Comprehensive Analysis of N-and O-Glycans Derived from Various Body Fluids and Their Exosomes | |
Ren et al. | Qualitative and Quantitative Methods for N-Glycans in N-Glycomics | |
Liu et al. | Integrated analysis of natural glycans using a versatile pyrazolone-type heterobifunctional tag ANPMP |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2517162 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005502815 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004703941 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004703941 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10546961 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10546961 Country of ref document: US |